Targeting a cell state common to triple‐negative breast cancers

• Published in: Molecular systems biology Vol. 11; no. 2; pp. 789 - n/a
• Main Authors: Muellner, Markus K, Mair, Barbara, Ibrahim, Yasir, Kerzendorfer, Claudia, Lechtermann, Hannelore, Trefzer, Claudia, Klepsch, Freya, Müller, André C, Leitner, Ernestine, Macho‐Maschler, Sabine, Superti‐Furga, Giulio, Bennett, Keiryn L, Baselga, José, Rix, Uwe, Kubicek, Stefan, Colinge, Jacques, Serra, Violeta, Nijman, Sebastian MB
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 01.02.2015; EMBO Press; BlackWell Publishing Ltd; Springer Nature
• Subjects: Addictions; Animals; Antineoplastic Agents - pharmacology; Apoptosis; Apoptosis - drug effects; Breast cancer; Cancer; Cancer therapies; Cell Differentiation - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; cell state; Cell Survival - drug effects; Clinical trials; Computer applications; Drug Delivery Systems; Drug dosages; EMBO03; EMBO17; EMBO28; Experiments; Female; Gene expression; Gene Expression Profiling; Genetic screening; Humans; Intracellular Signaling Peptides and Proteins - metabolism; Kinases; Leukemia; Life Sciences; Mice; Molecular Docking Simulation; Molecular Targeted Therapy; Mutation; Organic chemistry; Peptides; Protein Interaction Domains and Motifs; Protein kinase C; Protein-tyrosine kinase; Protein-Tyrosine Kinases - metabolism; Proteomics; Proteomics - methods; Selectivity; Sequence Analysis, RNA; Signal Transduction; small‐molecule screen; Spleen; Stat3 protein; STAT3 Transcription Factor - metabolism; Staurosporine - analogs & derivatives; Staurosporine - pharmacology; Studies; Syk Kinase; Syk protein; Transcription; Transforming Growth Factor beta - genetics; Transforming Growth Factor beta - metabolism; Triple Negative Breast Neoplasms - metabolism; Tumors; Tyrosine; Xenograft Model Antitumor Assays; breast cancer; small‐molecule screen; cell state; small-molecule screen

Some mutations in cancer cells can be exploited for therapeutic intervention. However, for many cancer subtypes, including triple‐negative breast cancer (TNBC), no frequently recurring aberrations could be identified to make such an approach clinically feasible. Characterized by a highly heterogeneo...